Differential correlation between rates of antimicrobial drug consumption and prevalence of antimicrobial resistance in a tertiary care hospital in Greece

Infection Control and Hospital Epidemiology

Volumn 29, Issue 7, 2008, Pages 615-622

  Iosifidis, Elias ^a   Antachopoulos, Charalampos ^a   Tsivitanidou, Maria ^a   Katragkou, Aspasia ^a   Farmaki, Evagelia ^a   Tsiakou, Maria ^b   Kyriazi, Theano ^b   Sofianou, Danai ^b   Roilides, Emmanuel ^a,c  

^a Hospital General Papageorgiou   (Greece)

^b Aristotle University of Thessaloniki   (Greece)

^c ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; ANTIINFECTIVE AGENT; CEFTAZIDIME; CIPROFLOXACIN; IMIPENEM; VANCOMYCIN;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG USE; ENTEROCOCCUS FAECIUM; ESCHERICHIA COLI; GREECE; HOSPITAL BED; HOSPITAL DEPARTMENT; HUMAN; KLEBSIELLA PNEUMONIAE; MICROBIOLOGICAL EXAMINATION; NONHUMAN; PREVALENCE; PSEUDOMONAS AERUGINOSA; TERTIARY HEALTH CARE;

ADULT; ANTI-BACTERIAL AGENTS; CHILD; CROSS INFECTION; DRUG RESISTANCE, BACTERIAL; ENTEROCOCCUS FAECIUM; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-POSITIVE BACTERIAL INFECTIONS; GREECE; HOSPITAL DEPARTMENTS; HOSPITALS; HUMANS; MICROBIAL SENSITIVITY TESTS; PREVALENCE;

EID: 47549096621     PISSN: 0899823X     EISSN: None     Source Type: Journal    
DOI: 10.1086/589333     Document Type: Article

References (33)

1. Giske CG, Monnet DL, Cars O, Carmeli Y; on behalf of ReAct-Action on Antibiotic Resistance. Clinical and economic impact of common multidrug-resistant gram-negative bacilli. Antimicrob Agents Chemother 2008;52:813-821.
2. Meyer E, Schwab F, Gastmeier P, Rueden H, Daschner FD. Surveillance of antimicrobial use and antimicrobial resistance in German intensive care units (SARI): a summary of the data from 2001 through 2004. Infection 2006;34:303-309.
3. Ferech M, Coenen S, Malhotra-Kumar S, et al. European Surveillance of Antimicrobial Consumption (ESAC): outpatient antibiotic use in Europe. J Antimicrob Chemother 2006;58:401-407.
4. White RL, Friedrich LV, Mihm LB, Bosso JA. Assessment of the relationship between antimicrobial usage and susceptibility: differences between the hospital and specific patient-care areas. Clin Infect Dis 2000;31:16-23.
5. Vander Stichele RH, Elseviers MM, Ferech M, Blot S, Goossens H. Hospital consumption of antibiotics in 15 European countries: results of the ESAC Retrospective Data Collection (1997-2002). J Antimicrob Chemother 2006;58:159-167.
6. Monroe S, Polk R. Antimicrobial use and bacterial resistance. Curr Opin Microbiol 2000;3:496-501.
7. Levy SB. The 2000 Garrod lecture. Factors impacting on the problem of antibiotic resistance. J Antimicrob Chemother 2002;49:25-30.
8. Gaynes R, Monnet D. The contribution of antibiotic use on the frequency of antibiotic resistance in hospitals. Ciba Found Symp 1997;207:47-56.
9. Sandiumenge A, Diaz E, Rodriguez A, et al. Impact of diversity of antibiotic use on the development of antimicrobial resistance. J Antimicrob Chemother 2006;57:1197-1204.
10. Austin DJ, Kristinsson KG, Anderson RM. The relationship between the volume of antimicrobial consumption in human communities and the frequency of resistance. Proc Natl Acad Sci U S A 1999;96:1152-1156.
11. Hsueh PR, Chen WH, Luh KT. Relationships between antimicrobial use and antimicrobial resistance in gram-negative bacteria causing nosocomial infections from 1991-2003 at a university hospital in Taiwan. Int J Antimicrob Agents 2005;26:463-472.
12. Frank U, Kleissle EM, Daschner FD, et al. Multicentre study of antimicrobial resistance and antibiotic consumption among 6,780 patients with bloodstream infections. Eur J Clin Microbiol Infect Dis 2006;25:815-817.
13. Mutnick AH, Rhomberg PR, Sader HS, Jones RN. Antimicrobial usage and resistance trend relationships from the MYSTIC Programme in North America (1999-2001). J Antimicrob Chemother 2004;53:290-296.
14. Neuhauser MM, Weinstein RA, Rydman R, Danziger LH, Karam G, Quinn JP. Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. JAMA 2003;289:885-888.
15. Martínez JA, Aguilar J, Almela M, et al. Prior use of carbapenems may be a significant risk factor for extended-spectrum β-lactamase- producing Escherichia coli or Klebsiella spp. in patients with bacteraemia. J Antimicrob Chemother 2006;58:1082-1085.
16. Lee SO, Kim NJ, Choi SH, et al. Risk factors for acquisition of imipenem-resistant Acinetobacter baumannii: a case-control study. Antimicrob Agents Chemother 2004;48:224-228.
17. Katragkou A, Kotsiou M, Antachopoulos C, et al. Acquisition of imipenem-resistant Acinetobacter baumannii in a pediatric intensive care unit: a case-control study. Intensive Care Med 2006;32:1384-1391.
18. Goossens H, Ferech M, Vander Stichele R, Elseviers M. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. Lancet 2005;365:579-587.
19. Fridkin SK, Steward CD, Edwards JR, et al. Surveillance of antimicrobial use and antimicrobial resistance in United States hospitals: project ICARE phase 2. Project Intensive Care Antimicrobial Resistance Epidemiology (ICARE) hospitals. Clin Infect Dis 1999;29:245-252.
20. MacDougall C, Powell JP, Johnson CK, Edmond MB, Polk RE. Hospital and community fluoroquinolone use and resistance in Staphylococcus aureus and Escherichia coli in 17 US hospitals. Clin Infect Dis 2005;41:435-440.
21. Bassetti M, Cruciani M, Righi E, et al. Antimicrobial use and resistance among gram-negative bacilli in an Italian intensive care unit (ICU). J Chemother 2006;18:261-267.
22. de With K, Meyer E, Steib-Bauert M, Schwab F, Daschner FD, Kern WV. Antibiotic use in two cohorts of German intensive care units. J Hosp Infect 2006;64:231-237.
23. Monnet DL. ABC Calc - antibiotic consumption calculator, version 1.9. Copenhagen, Denmark: Statens Serum Institut, 2003.
24. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing. 16th informational supplement. Wayne, PA: CLSI, 2006:M100-S16.
25. Hellenic Centre for Infectious Diseases Control (HCIDC) Web page. Available at: http://www.keel.org.gr/en/. Accessed December 31, 2007.
26. Livermore DM. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin Infect Dis 2002;34:634-640.
27. Livermore DM, Woodford N. The beta-lactamase threat in Enterobacteriaceae, Pseudomonas and Acinetobacter. Trends Microbiol 2006;14:413-420.
28. Lepper PM, Grusa E, Reichl H, Hogel J, Trautmann M. Consumption of imipenem correlates with β-lactam resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2002;46:2920-2925.
29. López-Lozano JM, Monnet DL, Yague A, et al. Modelling and forecasting antimicrobial resistance and its dynamic relationship to antimicrobial use: a time series analysis. Int J Antimicrob Agents 2000;14:21-31.
30. Miller GH, Sabatelli FJ, Hare RS, et al. The most frequent aminoglycoside resistance mechanisms - changes with time and geographic area: a reflection of aminoglycoside usage patterns? Aminoglycoside Resistance Study Groups. Clin Infect Dis 1997;24:S46-62.
31. Loeffler JM, Garbino J, Lew D, Harbarth S, Rohner P. Antibiotic consumption, bacterial resistance and their correlation in a Swiss university hospital and its adult intensive care units. Scand J Infect Dis 2003;35:843-850.
32. Lesch CA, Itokazu GS, Danziger LH, Weinstein RA. Multi-hospital analysis of antimicrobial usage and resistance trends. Diagn Microbiol Infect Dis 2001;41:149-154.
33. Ena J, Lopez-Perezagua MM, Martinez-Peinado C, Cia-Barrio MA, Ruiz-Lopez I. Emergence of ciprofloxacin resistance in Escherichia coli isolates after widespread use of fluoroquinolones. Diagn Microbiol Infect Dis 1998;30:103-107.